Rethinking Clinical Trials
SEPTEMBER 27, 2023
In this Friday’s PCT Grand Rounds, Claire Snyder of Johns Hopkins University and Norah Crossnohere and Anne Schuster, both of Ohio State University, will present “Navigating the Use of Patient-Reported Outcomes in Research and Practice: The PROTEUS Consortium.” The Grand Rounds session will be held on Friday, September 29, 2023, at 1:00 pm eastern.
Pharmaceutical Technology
SEPTEMBER 27, 2023
With GlobalData figures showing the value of pharma’s 2023 digital therapeutics-related deals to have grown by 129% since 2018, and the year still not out, it is clear that projects such as companion apps are becoming an increasing priority for life science firms. Here, we debate the benefits of building versus partnering, and share some important considerations for a successful project.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
SEPTEMBER 27, 2023
Report shows that if the health service invests in community services hospital admissions will reduce - News - PharmaTimes
Pharmaceutical Technology
SEPTEMBER 27, 2023
Arcturus Therapeutics has extended an existing agreement in place with the Cystic Fibrosis Foundation (CF Foundation) for advancing ARCT-032.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Times
SEPTEMBER 27, 2023
Patient waiting times to receive an appointment have reduced from 6-8 weeks to just 24 hours - News - PharmaTimes
Pharmaceutical Technology
SEPTEMBER 27, 2023
The idiopathic pulmonary fibrosis (IPF) market is underserved with just two licensed pharmaceutical treatments approved by the FDA in 2014.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
SEPTEMBER 27, 2023
Alfasigma has signed a definitive agreement for the acquisition of Intercept Pharmaceuticals in an all-cash deal valued at $794m.
Drug Discovery World
SEPTEMBER 27, 2023
HKG Epitherapeutics is a biotechnology company developing novel tools for the early detection of cancer and promoting healthy aging. Founder Dr Moshe Szyf Founder shares the potential of harnessing precision medicine. Embarking on a new era of medicine The advent of genomics has ushered in the era of personalised medicine, enabling us to analyse the genetic makeup of individuals with unprecedented accuracy.
Pharmaceutical Technology
SEPTEMBER 27, 2023
UKHSA has signed an advance purchase agreement (APA) with healthcare company CSL Seqirus for influenza pandemic vaccines.
BioPharma Reporter
SEPTEMBER 27, 2023
At Advanced Therapies Europe 2023, BioPharma Reporter caught up with ScaleReady's Jenny Stjernberg to discuss her work at the biotech company, her journey from academia to commercial and female representation in the cell and gene therapies industry.
Advertisement
There’s been a rapid shift towards decentralization in clinical trials & it’s clear why. The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. Tele visits, digital consent, new monitoring sensors, & direct-to-patient supply are virtual tools that existed before the pandemic, but now there’s swift adoption of these methods because they’ve been proven to help launch & complete trials more effectively.
Pharmaceutical Technology
SEPTEMBER 27, 2023
MilliporeSigma has opened two new messenger ribonucleic acid (mRNA) drug substance manufacturing facilities in Germany.
Drug Discovery World
SEPTEMBER 27, 2023
Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending dose design aims to rapidly identify the maximum tolerated dose for LEU011.
XTalks
SEPTEMBER 27, 2023
In this episode, Vera interviews Dr. Kristin Yarema, President of Cell Therapy at Poseida Therapeutics, about Poseida’s cell therapy approach and technologies. Dr. Kristin Yarema, President, Cell Therapy Poseida Therapeutics In April 2023, Dr. Yarema became the President of Cell Therapy at Poseida. She brings a wealth of knowledge from the biopharmaceutical realm, with expertise in oncology and allogeneic T-cell immunotherapy.
Drug Discovery World
SEPTEMBER 27, 2023
The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (DLd) for untreated multiple myeloma (MM) for routine use on the NHS in England and Wales. The therapy is now recommended within an NHS setting for the treatment of adults with newly diagnosed MM where an autologous stem cell transplant (ASCT) is unsuitable.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
XTalks
SEPTEMBER 27, 2023
EQUII, a food tech startup renowned for its protein bread that focuses on high complete protein and low carbs, is expanding its product line. This new range, which debuted at Expo East last week, includes Plain and Multigrain protein bread, delivering consumers a blend of nutrition without compromising on flavor. The company is also set to launch two more products that will be up for pre-order on its official website.
Drug Channels
SEPTEMBER 27, 2023
Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the great Drug Channels patch: A must-read report on hidden sources of PBMs’ profits How generic drugs drive specialty pharmacy profits CVS Health’s unadvertised 2022 drug trend report A shocking look at how PBMs set prescription prices Plus, Dr. Glaucomflecken teaches us about our insurance benefits.
XTalks
SEPTEMBER 27, 2023
Colorectal cancer, the third most frequently diagnosed cancer for both women and men in the US, continues to be a significant area of focus for the medical community. As advancements in research forge ahead, it is imperative to ensure patients are informed about and can access potentially life-saving clinical trials. Enter the Colorectal Cancer Alliance.
pharmaphorum
SEPTEMBER 27, 2023
Costco builds in telehealth with $29 online visit Phil.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
SEPTEMBER 27, 2023
Five strategies for delivering digital that makes a difference Mike.
pharmaphorum
SEPTEMBER 27, 2023
NICE turns down Enhertu in “devastating” move, says charity Phil.
pharmaphorum
SEPTEMBER 27, 2023
Ionis preps filings for olezarsen in rare disease FCS Phil.
pharmaphorum
SEPTEMBER 27, 2023
Ex-Novartis CMO John Tsai pops up at Forcefield Phil.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
pharmaphorum
SEPTEMBER 27, 2023
3rd mRNA-Based Therapeutics Summit Europe Mike.
Expert insights. Personalized for you.
147 
Let's personalize your content